Orexigen Gives The Skinny On Obesity Market During Contrave Update
This article was originally published in The Pink Sheet Daily
Orexigen discussed the dynamics of the obesity market as its 9,000-patient cardiovascular outcomes study for the diet pill Contrave gets underway.
You may also be interested in...
The company is optimistic it can work out an agreement with FDA to re-file the obesity drug application before it has interim data from a cardiovascular outcomes trial in hand.
A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies